Immunotherapy for Metastatic Melanoma: How It Works, Results and What to Expect

Immunotherapy for metastatic melanoma uses medicines that help the body’s immune system find and attack melanoma cells. It has changed the outlook for many people with stage 4 melanoma, although benefit, timing, and side effects differ from person to person.

Overview: immunotherapy for metastatic melanoma

Immunotherapy for metastatic melanoma is a systemic cancer treatment that strengthens or releases the body’s immune response against melanoma cells that have spread beyond the original skin site. It is commonly used for stage 4 melanoma and may also be considered for melanoma that cannot be fully removed with surgery. For many patients, it has become a central part of treatment planning because responses can sometimes continue for a long time after treatment has ended.

Metastatic melanoma can spread to lymph nodes or distant organs, including the lungs, liver, brain, bones, or other areas of skin. The treatment plan depends on where the cancer has spread, how quickly it is growing, symptoms, overall health, previous treatment, and molecular testing of the tumor. A melanoma team may combine immunotherapy with surgery, radiation therapy, targeted therapy, or supportive care when appropriate.

Modern immunotherapy most often refers to immune checkpoint inhibitors. These medicines do not kill cancer cells directly in the same way as chemotherapy. Instead, they help immune cells, particularly T cells, overcome signals that can prevent them from attacking melanoma. Melanoma should be assessed by an experienced multidisciplinary team, especially when it has spread or returned after earlier treatment.

How immunotherapy works

The immune system routinely checks the body for abnormal cells. Cancer cells can sometimes avoid this surveillance by using “checkpoint” signals that reduce immune activity. Checkpoint inhibitor medicines block selected checkpoint pathways, allowing immune cells to respond more actively to melanoma cells.

Medicines that target PD-1 are widely used in metastatic melanoma. In certain situations, a CTLA-4 inhibitor may be used alone or combined with a PD-1 inhibitor. Combination treatment can improve the chance of tumor response for some people, but it also increases the likelihood of significant immune-related side effects. The choice requires a careful discussion of expected benefit and risk.

Other immune-based approaches may be appropriate in selected circumstances, such as treatment with a virus-based therapy injected into accessible tumors or cell-based therapies at specialized centers. If a melanoma has a targetable genetic change, targeted medicines may be another important option. Immunotherapy treatment is therefore planned in the context of the individual tumor and the person’s clinical needs.

Who may be a candidate for treatment?

Many people with unresectable stage 3 melanoma or metastatic stage 4 melanoma may be considered for immunotherapy. Before treatment begins, the oncology team reviews pathology results, imaging, blood tests, medicines, medical history, and any symptoms caused by melanoma. Testing the tumor for changes such as BRAF mutations can help identify whether targeted therapy is also an option.

A person’s general fitness, organ function, and immune history matter. Immunotherapy may still be possible for people with some chronic conditions, but it needs particular care in those with autoimmune diseases, an organ transplant, active infection, significant lung disease, or a need for long-term immune-suppressing medicines. In these situations, specialists weigh the potential cancer benefit against the possibility of immune activation worsening another condition.

Brain metastases need prompt specialist assessment. Immunotherapy can be effective for some patients with melanoma in the brain, particularly when disease is small or asymptomatic, but treatment may also involve corticosteroids, surgery, or radiation therapy depending on the situation. Radiotherapy can be used to manage selected sites of disease and relieve symptoms, often alongside systemic treatment planning.

What happens during treatment and follow-up?

Before the first infusion, the care team explains the recommended medicine or combination, likely side effects, monitoring plan, and symptoms that should be reported urgently. Baseline tests commonly include blood counts and checks of liver, kidney, and thyroid function. Imaging scans establish a starting point for later comparison.

Checkpoint inhibitors are usually administered through a vein in an outpatient infusion unit. The infusion itself often takes a limited time, followed by observation if needed. Treatment schedules vary by medicine and regimen, commonly ranging from every few weeks to longer intervals. Most patients can return home the same day unless another medical issue requires admission.

There is no surgical recovery period, but ongoing monitoring is essential. The team reviews symptoms at each visit and repeats laboratory tests regularly because side effects may first appear in blood results. Scans are performed at planned intervals to evaluate the melanoma. Treatment may continue for a defined period, until maximum planned benefit, until unacceptable toxicity, or until there is clear evidence that the disease is progressing.

• Bring an up-to-date list of all medicines, supplements, and allergies to appointments.
• Ask the team which symptoms require a same-day call and who to contact outside office hours.
• Do not start steroids, herbal products, or new medicines without checking with the oncology team where possible.

How successful is immunotherapy for metastatic melanoma?

Immunotherapy has substantially improved treatment outcomes for metastatic melanoma compared with older approaches. Some people have a complete response, meaning scans no longer show detectable cancer, while others have a partial response or stable disease. For a proportion of patients, responses remain durable for years, including after immunotherapy is stopped.

However, there is no single success rate that applies to every patient. Outcomes vary with the immunotherapy regimen, tumor burden, sites of metastasis, tumor biology, previous treatments, general health, and whether serious side effects limit treatment. Combination checkpoint blockade can produce higher response rates in some clinical settings but also carries greater toxicity than single-agent treatment.

Clinical trial results provide useful averages, but they cannot predict one individual’s outcome. The treating oncologist can explain how published evidence applies to the person’s specific cancer, including whether a single agent, combination immunotherapy, targeted treatment, clinical trial, surgery, or radiation is most suitable.

How long can you live with stage 4 melanoma with immunotherapy? Survival with stage 4 melanoma varies widely. Some patients benefit for a relatively short period, while others have long-term disease control lasting years. Immunotherapy has made long-term survival possible for more patients than in the past, but it is not possible to estimate life expectancy accurately from stage alone; repeated scans, symptoms, treatment response, and overall health provide a more individualized picture.

How do you know if immunotherapy is working for melanoma?

The most reliable way to assess response is through scheduled imaging scans interpreted alongside clinical examination, symptoms, and blood tests. A reduction in the size or number of tumors may indicate response. Stable scans can also be a positive result when the melanoma was growing before treatment, because preventing further growth can be clinically meaningful.

Symptoms may improve when treatment is effective, such as less pain, breathlessness, fatigue related to disease, or reduced swelling from enlarged lymph nodes. However, symptoms alone cannot confirm whether treatment is working. Some people feel well even when scans show progression, while others have treatment side effects despite a good tumor response.

Occasionally, early scans may appear worse before later improvement because immune cells enter the tumor and cause inflammation. This uncommon pattern is called pseudoprogression. The oncology team distinguishes it from true progression by considering the scan pattern, the patient’s symptoms, follow-up imaging, and sometimes additional tests. Patients should not assume that new or worsening symptoms are a sign that treatment is working; they should report them promptly.

How long does it take for immunotherapy to work on melanoma? Responses may be seen within the first few months, but the timing varies considerably. Some tumors shrink early, while others respond more gradually. The care team usually schedules the first formal scan after several treatment cycles, although urgent symptoms or clinical concerns may lead to earlier assessment.

Benefits, risks, recovery, and self-care

The main potential benefit of immunotherapy is an immune response that controls or shrinks metastatic melanoma, sometimes for a long period. It can be used when melanoma is present in more than one area of the body and may help avoid or delay other treatments for some people. Yet not all melanomas respond, and additional treatment may be needed if the cancer progresses.

Because immunotherapy activates immune activity, side effects can occur when the immune system inflames healthy organs. More common effects include tiredness, rash, itching, diarrhea, nausea, joint aches, and changes in thyroid function. Less common but potentially serious effects can involve the lungs, liver, intestines, kidneys, heart, nerves, eyes, or hormone-producing glands. Side effects may occur during treatment or weeks to months after it ends.

Recovery is different for each person. Many continue daily activities between infusions, although fatigue may fluctuate. Adequate rest, regular gentle activity as tolerated, nourishing meals, hydration, skin protection, and emotional support can be helpful. The oncology team may prescribe medicines to manage immune-related inflammation, including corticosteroids, and may temporarily pause or permanently stop immunotherapy if needed.

Contact the treatment team promptly for persistent diarrhea, severe abdominal pain, new cough or shortness of breath, chest pain, fever, yellowing of the skin or eyes, severe headache, confusion, major weakness, vision changes, or a rapidly spreading rash. Early assessment often allows side effects to be treated more effectively and safely.

When to seek medical care

Anyone with a new or changing mole, a dark or unusual skin lesion, unexplained enlarged lymph nodes, or a history of melanoma with new persistent symptoms should arrange medical assessment. For people already diagnosed with metastatic melanoma, new symptoms should be shared with the oncology team rather than waiting for the next routine appointment.

Urgent medical advice is needed during or after immunotherapy for severe or rapidly worsening symptoms, especially breathing difficulty, chest pain, severe diarrhea, dehydration, confusion, fainting, high fever, severe weakness, or new neurological symptoms. Patients should tell emergency clinicians that they are receiving or have recently received an immune checkpoint inhibitor, as immune-related side effects require specific evaluation.

Care may involve medical oncology, dermatology, pathology, radiology, radiation oncology, surgical oncology, neurology, endocrinology, and supportive-care specialists. Acibadem International’s multidisciplinary specialists and JCI-accredited hospitals diagnose and treat melanoma for international patients, with treatment decisions guided by individual clinical assessment.

Frequently asked questions

Is immunotherapy a cure for metastatic melanoma?

Immunotherapy can produce complete and long-lasting responses in some people with metastatic melanoma. However, it does not work for every patient, and doctors generally avoid calling it a cure unless there is sufficient long-term evidence for an individual case. Ongoing follow-up remains important even after an excellent response.

Is combination immunotherapy better than one immunotherapy medicine?

Combination checkpoint inhibitor treatment may increase the likelihood of response in some patients. It also has a higher risk of immune-related side effects, some of which can be serious. The best approach depends on the extent of melanoma, symptoms, medical history, and the patient’s priorities.

Can immunotherapy be used if melanoma has spread to the brain?

Yes, immunotherapy may be considered for selected people with melanoma brain metastases. The treatment plan may also include surgery, corticosteroids, or radiation therapy depending on the number, size, location, symptoms, and urgency of the metastases. This situation should be managed by an experienced multidisciplinary team.

Can side effects happen after immunotherapy has stopped?

Yes. Immune-related side effects can occasionally begin or continue weeks or months after the last dose. Patients should inform any healthcare professional about prior immunotherapy and seek advice for new, persistent, or concerning symptoms.

What happens if immunotherapy does not work for metastatic melanoma?

The oncology team will reassess the cancer and discuss next options. These may include another immunotherapy strategy, targeted therapy when the tumor has an appropriate mutation, surgery or radiation for specific sites, a clinical trial, or supportive treatments. The next step is individualized and may depend on where and how quickly the melanoma is progressing.

Can a person work and exercise during melanoma immunotherapy?

Many people can continue some usual activities, including work and gentle exercise, depending on symptoms and treatment effects. Fatigue and immune-related side effects may require adjustments. Patients should discuss activity plans with their treatment team and stop or seek advice if they develop concerning symptoms.

References

• National Cancer Institute
• American Cancer Society
• European Society for Medical Oncology
• National Comprehensive Cancer Network
• Melanoma Research Alliance

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.